Entrada Therapeutics (NASDAQ:TRDA) COO Nathan Dowden Sells 3,116 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan Dowden sold 3,116 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $13.02, for a total value of $40,570.32. Following the sale, the chief operating officer owned 210,482 shares in the company, valued at approximately $2,740,475.64. This represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Entrada Therapeutics Price Performance

Shares of NASDAQ TRDA traded down $1.01 during trading hours on Thursday, reaching $12.49. The stock had a trading volume of 38,897 shares, compared to its average volume of 232,028. The company has a market cap of $478.19 million, a price-to-earnings ratio of -3.62 and a beta of -0.12. Entrada Therapeutics, Inc. has a twelve month low of $4.93 and a twelve month high of $13.65. The business’s fifty day moving average is $11.23 and its two-hundred day moving average is $8.86.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.38. The firm had revenue of $1.30 million for the quarter, compared to the consensus estimate of $7.41 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. Sell-side analysts forecast that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on TRDA shares. Guggenheim raised shares of Entrada Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 11th. Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. Finally, Oppenheimer began coverage on Entrada Therapeutics in a report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Entrada Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $18.50.

Institutional Investors Weigh In On Entrada Therapeutics

Large investors have recently made changes to their positions in the company. Royce & Associates LP boosted its position in Entrada Therapeutics by 54.8% in the third quarter. Royce & Associates LP now owns 345,507 shares of the company’s stock valued at $2,004,000 after buying an additional 122,256 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Entrada Therapeutics during the second quarter worth approximately $166,000. Los Angeles Capital Management LLC raised its stake in shares of Entrada Therapeutics by 60.6% in the second quarter. Los Angeles Capital Management LLC now owns 44,632 shares of the company’s stock valued at $300,000 after acquiring an additional 16,840 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Entrada Therapeutics in the third quarter valued at approximately $325,000. Finally, Great Lakes Advisors LLC acquired a new position in shares of Entrada Therapeutics in the 3rd quarter worth approximately $238,000. Institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.